国外新药美洛西林，以头孢呋肟为对照药进行随机对照临床试验，以呼吸系统及泌尿生殖系统细菌感染患者１２０例为研究对象，对其细菌学和临床疗效及安全性作出评价。结果显示：美洛西林和头孢呋肟临床有效率为９３．５％和９１．４％，细菌清除率为８７．１％和８１．０％，无统计学差别。不良反应发生率分别为４．８％和３．４％，无统计学差异。研究表明美洛西林为治疗常见感染性疾病高度有效而安全的抗生素。 Foreign new drug mezlocillin to cefuroxime as control drug for randomized controlled clinical trials of respiratory and genitourinary bacterial infections in 120 patients for the study of its bacteriological and clinical efficacy and safety evaluation. The results showed that the clinical effective rates of mezlocillin and cefuroxime were 93.5% and 91.4%, and the bacterial clearance rates were 87.1% and 81.0% respectively, with no statistical difference. The incidence of adverse reactions were 4.8% and 3.4%, respectively, with no significant difference. Research shows that mezlocillin is a highly effective and safe antibiotic for the treatment of common infectious diseases.